tiprankstipranks
Immucell Corp. (ICCC)
NASDAQ:ICCC

Immucell (ICCC) Stock Price & Analysis

68 Followers

ICCC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$4.26 - $6.05
Previous Close$5.14
Volume1.78K
Average Volume (3M)7.28K
Market Cap
$39.84M
Enterprise Value$54.53M
Total Cash (Recent Filing)$1.99M
Total Debt (Recent Filing)$16.68M
Price to Earnings (P/E)-6.9
Beta0.31
May 09, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding7,750,864
10 Day Avg. Volume6,363
30 Day Avg. Volume7,283
Standard Deviation0.13
R-Squared0.06
Alpha-0.00230
Financial Highlights & Ratios
Price to Book (P/B)1.54
Price to Sales (P/S)10.19
Price to Cash Flow (P/CF)-19.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.35
Enterprise Value/Gross Profit7.13
Enterprise Value/Ebitda-9.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

ICCC FAQ

What was Immucell Corp.’s price range in the past 12 months?
Immucell Corp. lowest stock price was $4.26 and its highest was $6.05 in the past 12 months.
    What is Immucell Corp.’s market cap?
    Currently, no data Available
    When is Immucell Corp.’s upcoming earnings report date?
    Immucell Corp.’s upcoming earnings report date is May 09, 2024 which is in 10 days.
      How were Immucell Corp.’s earnings last quarter?
      Immucell Corp. released its earnings results on Feb 27, 2024. The company reported -$0.147 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.147.
        Is Immucell Corp. overvalued?
        According to Wall Street analysts Immucell Corp.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Immucell Corp. pay dividends?
          Immucell Corp. does not currently pay dividends.
          What is Immucell Corp.’s EPS estimate?
          Immucell Corp.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Immucell Corp. have?
          Immucell Corp. has 7,750,864 shares outstanding.
            What happened to Immucell Corp.’s price movement after its last earnings report?
            Immucell Corp. reported an EPS of -$0.147 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.556%.
              Which hedge fund is a major shareholder of Immucell Corp.?
              Currently, no hedge funds are holding shares in ICCC
              ---

              Company Description

              Immucell Corp.

              ImmuCell Corp. engages in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. Its products include first defense for scours, California mastitis test kit and purified nisin intramammary treatment for mastitis. The company was founded in 1982 and is headquartered in Portland, ME.
              ---

              ICCC Company Deck

              ---

              ICCC Earnings Call

              Q4 2024
              0:00 / 0:00
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Intra-Cellular Therapies
              Immutep
              Pieris Pharmaceuticals
              Adverum Biotechnologies
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis